Andrew Fadden

Andrew Fadden currently serves as Chief Business Officer at Cytospire Therapeutics Ltd since January 2025. Prior to this role, Andrew held the position of Chief Business Officer at Enara Bio from July 2019 to April 2025. Experience includes serving as Director and Development Program Leader at Immunocore from November 2017 to July 2019, and as Director, Oncology Pipeline Lead in Global Regulatory Affairs at Vertex Pharmaceuticals from September 2015 to November 2017. Andrew began work in regulatory affairs as Associate Director at UCB between October 2010 and September 2015, and previously led regulatory projects as Regulatory Project Manager at GlaxoSmithKline from June 2007 to September 2010. Andrew's early career includes a Postdoctoral Research Fellowship at Cancer Research UK and a Postgraduate Research Assistantship at the University of Oxford. Andrew holds an M.Biochem in Molecular and Cellular Biochemistry from the University of Oxford, a PhD in Biochemistry from UCL, and an Executive MBA from the University of Warwick - Warwick Business School.